

Title (en)  
USE OF CD28 SPECIFIC MONOCLONAL ANTIBODIES FOR PRODUCING A PHARMACEUTICAL COMPOSITION FOR TREATING VIRUS INFECTIONS

Title (de)  
VERWENDUNG CD28 SPEZIFISCHER MONOKLONALER ANTIKÖRPER ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN ZUSAMMENSETZUNG ZUR BEHANDLUNG VON VIRUSINFEKTIONEN

Title (fr)  
UTILISATION D'ANTICORPS MONOCLONAUX SPECIFIQUES DE CD28 POUR PREPARER UNE COMPOSITION PHARMACEUTIQUE APPROPRIEE AU TRAITEMENT D'INFECTIONS VIRALES

Publication  
**EP 1200126 B1 20090422 (DE)**

Application  
**EP 00956124 A 20000727**

Priority  
• DE 0002596 W 20000727  
• DE 19939653 A 19990813

Abstract (en)  
[origin: DE19939653A1] The invention relates to the use of monoclonal antibodies which are specific for CD28 and activate the T lymphocytes of several up to all subgroups without the occupation of an antigen receptor of the T lymphocytes and which therefor activate said lymphocytes in an antigen unspecific manner or the invention relates to the use of an analogue thereof for producing a pharmaceutical composition in the form of a preparation or a preparation packet for treating virus infections in humans or lower warm-blooded animals having infected T lymphocytes. The pharmaceutical composition additionally contains a virus inhibitor. The invention also relates to a corresponding pharmaceutical composition and a treatment plan including the pharmaceutical composition.

IPC 8 full level  
**A61K 39/395** (2006.01); **A61K 31/47** (2006.01); **A61K 31/70** (2006.01); **A61P 31/12** (2006.01); **A61P 31/18** (2006.01); **C07K 16/28** (2006.01)

CPC (source: EP US)  
**A61K 31/7072** (2013.01 - EP US); **A61K 31/7076** (2013.01 - EP US); **A61K 38/05** (2013.01 - US); **A61K 39/3955** (2013.01 - US); **A61K 45/06** (2013.01 - US); **A61P 31/12** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **C07K 16/2818** (2013.01 - EP US); **A61K 2039/505** (2013.01 - EP US); **C07K 2317/30** (2013.01 - US)

Citation (examination)  
SUNTHARALINGAM ET AL: "Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412", NEW ENGLAND JOURNAL OF MEDICINE, vol. 355, no. 10, 7 September 2006 (2006-09-07), pages 1018 - 1028, XP002559375, DOI: doi:10.1056/NEJMoa063842

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Designated extension state (EPC)  
AL LT LV MK RO SI

DOCDB simple family (publication)  
**DE 19939653 A1 20010222**; AT E429248 T1 20090515; AU 6819600 A 20010313; DE 50015629 D1 20090604; DK 1200126 T3 20090727; EP 1200126 A1 20020502; EP 1200126 B1 20090422; ES 2326306 T3 20091007; PT 1200126 E 20090608; US 2007154468 A1 20070705; US 2011059071 A1 20110310; US 2015150968 A1 20150604; WO 0112224 A1 20010222

DOCDB simple family (application)  
**DE 19939653 A 19990813**; AT 00956124 T 20000727; AU 6819600 A 20000727; DE 0002596 W 20000727; DE 50015629 T 20000727; DK 00956124 T 20000727; EP 00956124 A 20000727; ES 00956124 T 20000727; PT 00956124 T 20000727; US 201414554590 A 20141126; US 34814409 A 20090102; US 70256007 A 20070206